Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial
No Thumbnail
Authors
Michalickova, Danica
Minić, Rajna

Dikić, Nenad

Anđelković, Marija
Kostić-Vučićević, Marija
Stojmenović, Tamara
Nikolić, Ivan
Đorđević, Brižita

Article (Published version)

Metadata
Show full item recordAbstract
A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severit...y and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.
Source:
Applied Physiology Nutrition and Metabolism, 2016, 41, 7, 782-789Publisher:
- Canadian Science Publishing, Nrc Research Press, Ottawa
Funding / projects:
Note:
- Peer-reviewed manuscript: http://farfar.pharmacy.bg.ac.rs/handle/123456789/3441
DOI: 10.1139/apnm-2015-0541
ISSN: 1715-5312
PubMed: 27363733
WoS: 000379430100013
Scopus: 2-s2.0-84977579626
Collections
Institution/Community
PharmacyTY - JOUR AU - Michalickova, Danica AU - Minić, Rajna AU - Dikić, Nenad AU - Anđelković, Marija AU - Kostić-Vučićević, Marija AU - Stojmenović, Tamara AU - Nikolić, Ivan AU - Đorđević, Brižita PY - 2016 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2753 AB - A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes. PB - Canadian Science Publishing, Nrc Research Press, Ottawa T2 - Applied Physiology Nutrition and Metabolism T1 - Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial VL - 41 IS - 7 SP - 782 EP - 789 DO - 10.1139/apnm-2015-0541 ER -
@article{ author = "Michalickova, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita", year = "2016", abstract = "A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.", publisher = "Canadian Science Publishing, Nrc Research Press, Ottawa", journal = "Applied Physiology Nutrition and Metabolism", title = "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial", volume = "41", number = "7", pages = "782-789", doi = "10.1139/apnm-2015-0541" }
Michalickova, D., Minić, R., Dikić, N., Anđelković, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism Canadian Science Publishing, Nrc Research Press, Ottawa., 41(7), 782-789. https://doi.org/10.1139/apnm-2015-0541
Michalickova D, Minić R, Dikić N, Anđelković M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism. 2016;41(7):782-789. doi:10.1139/apnm-2015-0541 .
Michalickova, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial" in Applied Physiology Nutrition and Metabolism, 41, no. 7 (2016):782-789, https://doi.org/10.1139/apnm-2015-0541 . .